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A B S T R A C T
Background
Mycoplasma pneumoniae (M. pneumoniae) is widely recognised as an important cause of community-acquired lower respiratory tract
infection (LRTI) in children. Pulmonary manifestations are typically tracheobronchitis or pneumonia but M. pneumoniae is also
implicated in wheezing episodes in both asthmatic and non-asthmatic individuals. Although antibiotics are used to treat LRTIs, a
review of several major textbooks offers conflicting advice for using antibiotics in the management of M. pneumoniae LRTI in children.
Objectives
To determine whether antibiotics are effective in the treatment of childhood LRTI secondary to M. pneumoniae infections acquired in
the community.
Search methods
We searched CENTRAL (2014, Issue 3), MEDLINE (1966 to July week 4, 2014), EMBASE (1980 to July, 2014), and both WHO
ICTRP and ClinicalTrials.gov (13 August 2014).
Selection criteria
Randomised controlled trials (RCTs) comparing antibiotics commonly used for treating M. pneumoniae (i.e. macrolide, tetracycline or
quinolone classes) versus placebo, or antibiotics from any other class in the treatment of children under 18 years of age with community-
acquired LRTI secondary to M. pneumoniae.
Data collection and analysis
The review authors independently selected trials for inclusion and assessed methodological quality. We extracted and analysed relevant
data separately and resolved disagreements by consensus.
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Main results
A total of 1912 children were enrolled from seven studies. Data interpretation was limited by the inability to extract data that referred
to children with M. pneumoniae. In most studies, clinical response did not differ between children randomised to a macrolide antibiotic
and children randomised to a non-macrolide antibiotic. In one controlled study (of children with recurrent respiratory infections, whose
acute LRTI was associated with Mycoplasma, Chlamydia or both, by polymerase chain reaction and/or paired sera) 100% of children
treated with azithromycin had clinical resolution of their illness compared to 77% not treated with azithromycin at one month.
Authors’ conclusions
There is insufficient evidence to draw any specific conclusions about the efficacy of antibiotics for this condition in children (although
one trial suggests macrolides may be efficacious in some children with LRTI secondary to Mycoplasma). The use of antibiotics has to
be balanced with possible adverse events. There is still a need for high quality, double-blinded RCTs to assess the efficacy and safety of
antibiotics for LRTI secondary to M. pneumoniae in children.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics to treat respiratory infections caused by the bacteria Mycoplasma pneumoniae in children
Review question
This review sought to answer the question of whether antibiotics are effective in the treatment of LRTIs caused by the bacteria
Mycoplasma pneumoniae (M. pneumoniae) in children.
Background
M. pneumoniae is a bacterial infection, often responsible for lower respiratory tract infections (LRTIs) in children. The infection can
present in a number of different ways and the most common respiratory manifestations are acute bronchitis, pneumonia or wheezing.
The illness is generally self limiting, with symptoms that can last several weeks but may (occasionally) also cause severe pneumonia.
Antibiotics are often given to children with M. pneumoniae LRTI.
Search date
We searched for trials published and pending as at July 2014.
Study characteristics
Randomised controlled trials (RCTs) comparing either two types of antibiotic therapy or an antibiotic versus a placebo in children with
pneumonia.
Key results
We identified seven studies (1912 children). Within each study, there were some children who had M. pneumoniae but we could not
extract relevant data relating to efficacy or adverse events relating only to children with M. pneumoniae.
Quality of evidence
Overall the quality of the evidence for each of the main outcomes is very low as there are insufficient data for any outcome. Hence,
currently, there is insufficient evidence to show conclusively that antibiotics are effective in childrenwith LRTI caused byM. pneumoniae.
B A C K G R O U N D
Description of the condition
Mycoplasma pneumoniae (M. pneumoniae) is widely recognised as
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an important cause of community-acquired lower respiratory tract
infection (LRTI) in children, accounting for 14% to 34% of cases
(Kogan 2003; Michelow 2004; Nelson 2002; Principi 2002). The
highest attack rates are reported to occur in five to 20-year olds and
the infection is usually self limiting, with symptoms lasting several
weeks (Nelson 2002; Rudolph 2003). More recently, M. pneumo-
niae has been identified as an important cause of LRTI in children
under five years of age (Principi 2001). Pulmonary manifestations
are typically tracheobronchitis or pneumonia but can be compli-
cated by pleural effusion, lung abscess, pneumothorax, bronchiec-
tasis and respiratory distress syndrome (Principi 2002). M. pneu-
moniae is also implicated in wheezing episodes in both asthmatic
and non-asthmatic individuals (Phelan 1994; Principi 2001). Un-
common extrapulmonary manifestations may include erythema
multiforme, myocarditis, encephalitis, Guillain-Barré syndrome,
transverse myelitis and haemolytic anaemia (Nelson 2002; Waites
2003). Radiographic findings are quite variable and non-diagnos-
tic (Principi 2001). In some cases there can be significant radio-
logical changes in the absence of clinical signs on auscultation of
the chest (so-called ’walking pneumonia’) (Rudolph 2003).
Description of the intervention
Antibiotics are frequently used to treat LRTIs and empiric antibi-
otic therapy is often chosen to cover both bacteria and atypical
organisms (Kogan 2003). A review of several major textbooks of-
fers conflicting advice for management of M. pneumoniae LRTI.
The chapter on M. pneumoniae in a paediatric respiratory text-
book mentions that there is little evidence of beneficial effect from
antibiotic therapy (Phelan 1994). This is in contrast to the rec-
ommendations in a major general paediatric textbook (Rudolph
2003), and paediatric infectious disease textbook (Katz 1998),
which state that erythromycin is the treatment of choice.
How the intervention might work
The use of antibiotics in treating LRTI in children would be ex-
pected to reduce the severity or duration (or both) of the infection
and its associated symptoms.
Why it is important to do this review
The conclusion that antibiotics are effective in M. pneumoniae
chest infections seems to have been drawn from trials of antibiotic
therapy for community-acquired or atypical pneumonia, where
M. pneumoniae was identified as a causative organism in a sub-
group of cases. In these studies, macrolide antibiotics, to which M.
pneumoniae is susceptible, have been compared to non-macrolide
antibiotics. However, it is not always possible to draw meaningful
conclusions from the results, as the numbers of individuals with
M. pneumoniae are small in most trials (Block 1995; Kogan 2003;
Wubbel 1999).
Identification of M. pneumoniae infection as the causative infec-
tious agent may, however, pose difficulties. Serological tests are
the most common method used to diagnose M. pneumoniae in-
fections, but can lead to difficulties with interpretation (Principi
2001). Measurement of immunoglobulin M (IgM) is used to di-
agnose acute infection, but the accuracy of the test depends on the
method used. Not all methods are specific for IgM and an elevated
IgM may persist for months after the acute infection (Murray
2003). Immuno-fluorescent antibody (IFA) assay is more sensi-
tive and specific than the complement fixation (CF) test (Murray
2003; Principi 2001). Identification ofM. pneumoniae in nasopha-
ryngeal secretions by culture or polymerase chain reaction (PCR)
may also cause difficulties with interpretation as this organism can
persist for variable periods following the acute infection (Murray
2003). The ’gold standard’ for diagnosis of M. pneumoniae infec-
tion is a four-fold increase in total antibody titre as measured in
paired sera (Katz 1998; Murray 2003).
O B J E C T I V E S
To determine whether antibiotics are effective in the treatment of
childhood LRTI secondary to M. pneumoniae infections acquired
in the community.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing antibiotics from
the macrolide, tetracycline or quinolone class (i.e. antibiotics that
are efficacious for Mycoplasma) versus placebo, or antibiotics from
any other class (i.e. medications that are not efficacious for my-
coplasma).
Types of participants
Trials that included children under 18 years of age with commu-
nity-acquired LRTI secondary to M. pneumoniae. Diagnosis of M.
pneumoniae infection was via either a four-fold rise in total anti-
body titre from paired sera or total antibody titre ≥ 1:512 on a
single specimen. We included other methods of diagnosis, such as
culture or PCR of M. pneumoniae in nasopharyngeal secretions or
demonstration of elevated IgM on a single specimen (IgM titre ≥
1:10), and analysed these separately as a subgroup.
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Exclusion criteria
1. Children with underlying chronic cardiorespiratory
illnesses, such as cystic fibrosis, bronchiectasis,
immunodeficiency, chronic neonatal lung disease and
symptomatic congenital heart disease.
2. Children with non-community-acquired LRTI.
Types of interventions
We evaluated two separate treatment regimes.
1. Any antibiotic versus placebo.
2. Antibiotics from the macrolide, tetracycline or quinolone
class versus placebo or antibiotics from any other class.
We included trials that allowed the use of other medications or
interventions in addition to antibiotic therapy if all participants
had equal access to such medications or interventions.
Types of outcome measures
Wemade attempts to obtain data on at least the following outcome
measures.
Primary outcomes
1. Proportions of participants who were not improved at
follow-up. We measured failure to improve according to the
hierarchy listed below.
Secondary outcomes
1. Mean difference in symptoms and signs (mean
improvement in clinical state).
2. Proportions requiring hospitalisation.
3. Proportions experiencing pulmonary complications
(empyema, pleural effusion, air leak).
4. Proportions experiencing non-pulmonary complications.
5. Proportions experiencing adverse effects (for example,
nausea, diarrhoea, abdominal pain, rash).
6. Proportions experiencing complications (for example,
requirement for medication change).
We determined the proportions of participants who failed to im-
prove on treatment and the mean clinical improvement using the
following hierarchy of assessment measures. (We reported all out-
comes, but where two or more assessment measures were reported
in the same study and we obtained conflicting results, we used the
outcome measure that was listed first in the hierarchy).
1. Objective measurements of cough indices (cough
frequency).
2. Symptomatic (cough, wheeze, dyspnoea, malaise, general
well-being, headache): assessed by the child (Likert scale, visual
analogue scale, level of interference of symptoms, diary, quality
of life).
3. Symptomatic (cough, wheeze, dyspnoea, malaise, general
well-being, headache): assessed by the parents/carers (Likert
scale, visual analogue scale, level of interference of symptoms,
diary, quality of life).
4. Symptomatic (cough, wheeze, dyspnoea, malaise, general
well-being, headache): assessed by the clinician (Likert scale,
visual analogue scale, level of interference of symptoms, diary,
quality of life).
5. Fever.
6. Non-clinical outcomes (chest radiology, white cell count, C-
reactive protein, erythrocyte sedimentation rate, lung function).
7. Eradication of M. pneumoniae by PCR evaluation.
Search methods for identification of studies
Electronic searches
For this 2014 update we searched the Cochrane Central Register
of Controlled Trials (CENTRAL) (2014, Issue 3) (accessed 8 July
2014) limited to year published 2011 to 2014, which contains the
Acute Respiratory Infection Group’s Specialised Register, MED-
LINE (1 January 2012 to June week 4, 2014) and EMBASE (1
January 2012 to July 2014).
Previously we searched the Cochrane Central Register of Con-
trolled Trials (CENTRAL) (2012, Issue 2) (accessed 13 March
2012), which contains the Acute Respiratory Infection Group’s
SpecialisedRegister,MEDLINE (1966 to FebruaryWeek 5, 2012)
and EMBASE (1980 to March 2012). Details of earlier searches
are described in Appendix 1.
We used the search terms in Appendix 2 to search MEDLINE
and CENTRAL.We combined theMEDLINE search with a sen-
sitive search strategy for identifying child studies (Boluyt 2008)
and the Cochrane Highly Sensitive Search Strategy for identifying
randomised trials in MEDLINE: sensitivity-maximising version
(2008 revision); Ovid format (Lefebvre 2011). We adapted the
search terms for EMBASE (Appendix 3).
We imposed no language or publication restrictions.
Searching other resources
We searched the World Health Organization International Clini-
cal Trials Registry Platform (WHO ICTRP) and the US National
Institute of Health ClinicalTrials.gov platform (Appendix 4) for
all registered trials, both published and pending, as at 13 August
2014. We further manually checked all references for reports of
trials.
Data collection and analysis
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Selection of studies
In the first publication of this review, three review authors (JG,
AC, SM) independently reviewed the literature searches from the
title, abstract or descriptions, to identify potentially relevant trials
for full review. We conducted searches of bibliographies and texts
to identify additional studies. Three review authors (JG, AC, SM)
independently selected trials for inclusion from the full text using
specific criteria. In the 2012 update two review authors (MG, AC)
reviewed the literature searches. For this 2014 update two review
authors (SG, AC) independently assessed the literature searches
for inclusion and exclusion.
Data extraction and management
In the first publication of this review, three review authors (JG,
AC, SM) independently extracted data and resolved disagreement
by consensus. We reviewed trials that satisfied the inclusion cri-
teria and recorded the following information: study setting; year
of study; source of funding; patient recruitment details (includ-
ing number of eligible children); inclusion and exclusion crite-
ria; randomisation and allocation concealment method; numbers
of participants randomised; blinding (masking) of participants,
care providers and outcome assessors; intervention (type of an-
timicrobials, dose, duration); control (type, dose, duration); co-
interventions; numbers of patients not followed up; reasons for
withdrawals from study protocol (clinical, side effects, refusal and
other); details on side effects of therapy; and whether intention-
to-treat (ITT) analyses were possible. We extracted data on the
outcomes described previously. The review authors requested fur-
ther information from the study authors where required.
Assessment of risk of bias in included studies
In the original review, two review authors (JG, AC) utilised the
Jadad quality assessment scores (Gavranich 2005). In the 2012
update three review authors (JG, AC, SM) independently assessed
the quality of studies included in the review using the ’Risk of
bias’ table available in Review Manager 5 (RevMan 2014), in ac-
cordance with the guidelines in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). We assessed five
components of quality.
1. Adequate sequence generation. This assesses the quality of
the method of randomisation.
2. Allocation concealment. This assesses whether or not
enrolling staff were aware of the group to which participants
would be allocated.
3. Blinding. This assesses the extent of blinding, with
participant/caregiver and outcome assessor blinding taken into
account.
4. Follow-up. This assesses whether the proportion of
participants lost to follow-up is admissible, and whether
adequate reasons for the losses were made available.
5. Reporting of participants by allocation group. This assesses
whether the results were reported relative to the treatment
groups.
Measures of treatment effect
In the protocol we planned to calculate relative and absolute risk
reductions using an ITT analysis for the dichotomous outcome
variables of each individual study. However, data were unavailable.
Dealing with missing data
The review authors wrote to the trial authors to enquire about
availability of data but we did not receive any replies.
Assessment of heterogeneity
In the protocol we planned to describe any heterogeneity between
the study results and, depending upon the number of trials in-
cluded in the review, we had planned to use a funnel plot to look
for publication bias. However, data were unavailable and we were
unable to include any studies in a meta-analysis.
Data synthesis
In the protocol we planned to include the results from studies that
met the inclusion criteria and report any of the outcomes of inter-
est in the subsequent meta-analysis. We planned to calculate the
summary weighted risk ratio (RR) and 95% confidence interval
(CI) (fixed-effect model) using the inverse of the variance of each
study result for weighting. We planned to calculate the number
needed to treat to benefit using the summary odds ratio (OR) and
the average control event rate described in the relevant studies. We
stated in the protocol that the cough indices were assumed to be
normally distributed continuous variables so the mean difference
(MD) in outcomes could be estimated. In studies that reported
outcomes using different measurement scales, we would have es-
timated the standardised MD. However, data were unavailable.
Subgroup analysis and investigation of heterogeneity
In the protocol we intended to perform an a priori subgroup anal-
ysis for the following.
1. Children aged seven years and older.
2. Intervention type (class of antibiotics).
3. Diagnostic criteria used for identification of M. pneumoniae.
However, data were unavailable.
Sensitivity analysis
In the protocol we planned a sensitivity analysis to assess the impact
of the potentially important factors on overall outcomes.
1. Study quality.
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2. Study size.
3. Variation in the inclusion criteria.
4. Differences in the medications used and duration of
treatment in the intervention and comparison groups.
5. Differences in outcome measures.
6. Analysis by ’treatment received’ rather than ITT.
However, data were unavailable.
R E S U L T S
Description of studies
Results of the search
We identified 91 potentially relevant titles in the initial search.
After reviewing the abstracts, we obtained 17 papers in full text
for consideration for inclusion in the review. We included seven
studies and details are provided in the Characteristics of included
studies table. Three of the included studies were non-English:
German (Ruhrmann 1982) and Spanish (Gomez Campdera 1996;
Saez-Llorens 1998).
In the updated search in 2009 we identified 20 new records, of
which we considered 11 for inclusion, but only included one
(Esposito 2005). We excluded two as they did not meet the in-
clusion criteria (Bradley 2007; Lee 2008), two had no focus on
the aetiology of the LRTI (Bradley 2007; Fonseca-Aten 2006),
and three were review papers including the most recent review
(Atkinson 2007). One only focused on upper respiratory tract in-
fections (URTIs) (Esposito 2006), one result was the previous ver-
sion of this review (Gavranich 2005), and one paper was unavail-
able for evaluation (Simon 2006). In the 2012 search we identified
77 studies, though none fulfilled the inclusion criteria.
In this 2014 search we identified a total of 22 studies and none
fulfilled the specified inclusion criteria.
Included studies
Participants
The studies involved children diagnosed with LRTI ranging in age
from one month to 16 years. In all except three studies (Esposito
2005; Gomez Campdera 1996; Soderstrom 1991) children had
pneumonia supported with abnormal chest X-ray, and apart from
two studies (Esposito 2005; Ruhrmann 1982) the children were
described as having community-acquired pneumonia. The study
by Gomez Campdera 1996 did not define pneumonia and the
study by Soderstrom 1991 included participants with acute bron-
chitis. The number of children with M. pneumoniae causing LRTI
was not stated in four studies (Esposito 2005; Gomez Campdera
1996; Ruhrmann 1982; Saez-Llorens 1998). In one study there
were 12 children with M. pneumoniae infections and six were in
the subgroup randomised to either azithromycin or amoxycillin-
clavulanate, but the number assigned to each therapy was not
available (Wubbel 1999). In two other studies the number of chil-
dren with M. pneumoniae infections in each intervention group
was provided. In the study by Harris 1998 there were 30 children
who had M. pneumoniae infections randomised to either azithro-
mycin or amoxycillin-clavulanate (21 in the azithromycin group
and nine in the amoxycillin-clavulanate group) and there were
eight children in the study by Kogan 2003 (five in the azithro-
mycin group and three in the amoxycillin-clavulanate group). In
the study by Soderstrom 1991 there were only seven patients with
LRTI (bronchitis) and one case of M. pneumoniae, but the age of
the participants with M. pneumoniaewas not provided. The study
by Esposito 2005 did not distinguish between upper and lower
respiratory tract infections in their analysis of results, although the
number of M. pneumoniae infections (which included both UR-
TIs and LRTIs) was made available.
Interventions
Studies included in this review involved patients with LRTI ran-
domised to either a macrolide antibiotic or another antibiotic,
usually a different macrolide or non-macrolide antibiotic. In
two studies the entire study population was randomised to ei-
ther a macrolide or non-macrolide antibiotic (Ruhrmann 1982;
Soderstrom 1991). Ruhrmann 1982 included children with pneu-
monia who received either erythromycin 70 to 80 mg/kg/day or
amoxycillin 60 to 70 mg/kg/day. The duration of therapy was not
stated. The study by Soderstrom 1991 had a subgroup of par-
ticipants (number of children not stated) with acute bronchitis
who received either erythromycin 500 mg twice daily for seven
days or phenoxymethylpenicillin 800 mg twice daily for seven
days. Four studies randomised a subgroup of children under five
years of age to azithromycin or amoxycillin-clavulanate (Gomez
Campdera 1996; Harris 1998; Saez-Llorens 1998;Wubbel 1999).
The dose of amoxycillin-clavulanate was 40 mg/kg/day in three
divided doses for 10 days in all studies. The dose of azithromy-
cin was 10 mg/kg once daily for three days in one study (Gomez
Campdera 1996) and 10 mg/kg on day one followed by 5 mg/
kg once daily for day two to five in three studies (Harris 1998;
Saez-Llorens 1998; Wubbel 1999). In the study by Kogan 2003
the intervention for the subgroup with classic pneumonia was ei-
ther azithromycin 10 mg/kg once daily for three days or amoxy-
cillin 75 mg/kg/day in three divided doses for seven days. The
Esposito 2005 study compared azithromycin with symptom-spe-
cific agents to symptom-specific agents alone; the azithromycin
that was given was 10 mg/kg/day, three days per week for three
weeks and acetaminophen (at 10 mg/kg/dose) was the symptom-
specific agent.
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Outcome measures
Clinical
Clinical response was the main outcome but was not defined
in three studies (Gomez Campdera 1996; Ruhrmann 1982;
Soderstrom 1991). In three studies clinical cure was defined as
complete resolution of symptoms and signs by day 15 to 19 (Harris
1998), day 10 to 25 (Saez-Llorens 1998) and day 10 to 37 (Wubbel
1999). In the study by Kogan 2003 the clinical response was de-
fined as the proportion of children without fever on day three.
The Esposito 2005 study evaluated clinical responses at both one
month (defined as the complete resolution of the acute symptoms,
with no relapse) and six months (defined as the presence of no
more than two respiratory relapses).
Radiological
Radiological outcome was recorded in three studies (Gomez
Campdera 1996; Harris 1998; Kogan 2003), but was not de-
fined in the study by Gomez Campdera 1996. Bacteriological
outcome was recorded in three studies (Esposito 2005; Harris
1998; Saez-Llorens 1998), but was not defined in the study by
Saez-Llorens 1998. Adverse events were recorded in four stud-
ies (Gomez Campdera 1996; Harris 1998; Saez-Llorens 1998;
Wubbel 1999), but were only defined in the study byHarris 1998.
We made attempts to obtain individual patient data from four
studies (Esposito 2005;Harris 1998; Kogan 2003;Wubbel 1999),
where the number of children with LRTI due to M. pneumoniae
was not identified, but we did not receive a reply at the time this
review was completed.
Excluded studies
We have excluded 19 papers and details are provided in the
Characteristics of excluded studies table. The main reasons for
exclusion were the non-randomised nature of the study (Jensen
1967; Sakata 2001; Vasilos 1995), or use of inadequate placebo or
comparator (Block 1995; Bradley 2007; Chien 1993; Jensen 1967;
Lee 2008; Lee 2012; Manfredi 1992; Nogeova 1997; Ronchetti
1994; Schonwald 1990; Sempertegui 2014; Wu 2014; Yin 2002).
Three of the excluded studies were non-English: Japanese (Sakata
2001), Russian (Vasilos 1995) and Chinese (Yin 2002).
Risk of bias in included studies
We assessed risk of bias using the ’Risk of bias’ tables for included
studies (see Characteristics of included studies) (Higgins 2011).
We generated a graph and summary for the information, and the
combined results for the different categories of risk are highlighted.
Approximately 50% of included studies were not blinded, but
good results were seen for both follow-up and reporting of par-
ticipants by allocation group overall (i.e. in more than half the
included studies these were not found to be a source of bias).
Allocation
All studies were described as randomised and the method of ran-
domisation was clearly described and appropriate in three studies
where a random number list was used (Esposito 2005; Ruhrmann
1982; Saez-Llorens 1998). The method of randomisation was un-
clear in one study where the method used was described as a list
of randomised therapy assignments (Wubbel 1999). In the trial
Soderstrom 1991, the method used was sequential patient num-
bers and we thought this to be inadequate. Three studies did not
describe the method of randomisation (Gomez Campdera 1996;
Harris 1998; Kogan 2003). Concealment of allocation was un-
clear in all except three studies; two assigned therapy by pharmacy
(Saez-Llorens 1998;Wubbel 1999), and one allocated the duties of
enrolment and randomisation to separate investigators (Esposito
2005).
Blinding
There was no blinding in four studies (Gomez Campdera 1996;
Ruhrmann 1982; Saez-Llorens 1998; Wubbel 1999). In three
studies the blinding involved only the participant (Harris 1998),
clinician (Kogan 2003) or radiologist (Soderstrom 1991). The
Esposito 2005 study blinded the participant, caregiver, clinical
outcome assessors and data/statistical analysts.
Incomplete outcome data
Five of the included studies adequately followed up their partic-
ipants. Three of the eight included studies had unclear levels of
follow-up. Gomez Campdera 1996 and Ruhrmann 1982 made
no mention of losses to follow-up. While Saez-Llorens 1998 men-
tioned that 30 were lost to follow-up, there was no mention of
why or from which groups these losses occurred.
Selective reporting
Although selective reporting was not readily identified, possible
issues are highlighted in Other potential sources of bias.
Other potential sources of bias
Three of the eight included studies were funded by Pfizer Incorpo-
rated, a large pharmaceutical company responsible for producing
Zithromax, a popular azithromycin (Esposito 2005; Harris 1998;
Wubbel 1999). This association may have influenced the subjec-
tive outcome measures of these studies (i.e. ’clinical success’). All
three studies were concerned with the efficacy of azithromycin in
treating LRTIs, and none found it to be a less effective drug than
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alternative antimicrobial therapy. Wubbel 1999 found no differ-
ence and Esposito 2005 and Harris 1998 found it to be a superior
treatment.
Effects of interventions
Ideally the primary and secondary outcomes should be reported
here but the lack of data relevant for M. pneumoniae within each
study precludes this and hence the data described below relate to
the studies themselves where the subgroup was reported.
We identified seven trials with 1912 children. The number of
children from one study was unavailable (Soderstrom 1991).
Data interpretation was significantly limited by the inability to
extract data that specifically referred to children with lower respi-
ratory tract infection (LRTI) caused byM. pneumoniae. There was
only one study of children randomised to any antibiotic versus
placebo (Esposito 2005). Most of the included studies comprised
a subgroup of children who were randomised to a macrolide ver-
sus non-macrolide antibiotic. The total number of children in this
subgroup was not known as the numbers were only available in
four studies (Harris 1998; Kogan 2003; Ruhrmann 1982;Wubbel
1999). The number of children with LRTI secondary to M. pneu-
moniae in this subgroup was only available in two studies (Harris
1998; Kogan 2003), and the lack of individual patient data did
not allow for inclusion of results in a meta-analysis. There was a
total of 26 in the azithromycin group and 12 in the amoxycillin-
clavulanate group.
In the study by Gomez Campdera 1996 the rate of clinical cure
was 95.12% in the azithromycin group and 90.41% in the amoxy-
cillin-clavulanate group. Radiological improvement was noted in
90.6% of the azithromycin group. Adverse events were recorded
in 11.25% of the azithromycin group and 17.14% in the amoxy-
cillin-clavulanate group. Harris 1998 reported no difference in the
rate of clinical cure at day 15 to 19 (67.2% versus 66.7%) and
four to six weeks (85.1% versus 85.4%) in children randomised
to azithromycin or amoxycillin-clavulanate. M. pneumoniae was
identified in 16% (30 of 188 children under five years of age).
Eradication of M. pneumoniae occurred in 3/3 in the azithromycin
group and in 0/1 in the amoxycillin-clavulanate group. Adverse
events in those children under five years of age were 12.1% in
the azithromycin group and 42.3% in the amoxycillin-clavulanate
group.
One participant in each group discontinued treatment because
of adverse events. In the study by Kogan 2003, which compared
azithromycin to amoxicillin in children with classical pneumonia
(eight children of 47 had M. pneumoniae), X-ray resolution was
significantly better in those treated with azithromycin (81% ver-
sus 60.9% at day seven), but there was no difference in clinical
symptoms or signs between groups. In those with atypical pneu-
monia (23 children of 59 hadM. pneumoniae) there was no signifi-
cant difference between children treated with azithromycin or ery-
thromycin (Kogan 2003). Ruhrmann 1982 reported clinical cure
after 3.79 days in the erythromycin group and 3.96 days in the
amoxycillin group. Saez-Llorens 1998 reported a similar clinical
response (99% versus 98%) in children under five years who were
randomised to azithromycin or amoxycillin-clavulanate. Eradica-
tion of M. pneumoniae occurred in 23 out of 24 in the azithro-
mycin group. Adverse events were reported in 11% on azithromy-
cin, 30% on amoxycillin-clavulanate and 27% on erythromycin.
Soderstrom 1991 did not report the clinical response in the sub-
group of patients with bronchitis. In the study by Wubbel 1999,
where 7% (12 of 168 children) had M. pneumoniae, no difference
was found in children randomised to azithromycin or amoxicillin-
clavulanate. Adverse events were reported in 14% on azithromy-
cin, 67% on amoxycillin-clavulanate and 25% on erythromycin.
Eleven patients did not complete the prescribed therapy. Esposito
2005, which groupedChlamydia pneumoniae (C. pneumoniae) and
M. pneumoniae together (and did not distinguish between up-
per and lower respiratory tract infections) when reporting clinical
success rates (with a total of 200/560 infected children), found a
100% success rate in the short term with azithromycin and symp-
tomatic therapy, and a 73.2% success rate at the six-month follow-
up. Symptomatic treatment alone showed a success rate of 77.2%
at one month and 56.0% at six months. Adverse events were not
reported in this study.
D I S C U S S I O N
Summary of main results
This review failed to find any randomised controlled trials (RCTs)
that specifically looked at the effectiveness of antibiotics for lower
respiratory tract infection (LRTI) secondary to M. pneumoniae.
There was only one study of antibiotics versus placebo (Esposito
2005), but this study defined success rates relative to LRTI sec-
ondary to M. pneumoniae and Chlamydia defined by polymerase
chain reaction (PCR) or paired sera. In this study significantly
more children in the azithromycin group had ’clinical success’ on
follow-up than the placebo group. From the other studies, in the
subgroup of children with LRTI secondary to M. pneumoniae the
intervention was a macrolide antibiotic versus a non-macrolide
antibiotic, usually amoxycillin-clavulanate. This subgroup identi-
fied only 38 children with M. pneumoniae infection and there were
insufficient data to analyse the efficacy of macrolide antibiotics
in this group. Adverse events were common: reported in 11% to
67% of children. The majority of adverse events related to the
gastrointestinal tract (diarrhoea, vomiting, abdominal pain, nau-
sea, anorexia) and where reported were more common in younger
children (under five years of age).
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Overall completeness and applicability of
evidence
There were significant difficulties in interpreting the data from the
included studies. Firstly, although all studies (except Soderstrom
1991) enrolled children with LRTI, only a proportion had M.
pneumoniae infection. It was not possible to obtain information
on the subgroup with M. pneumoniae. Secondly, the dose and
type of antibiotics differed among studies. Thirdly, application
of diagnostic criteria (serology versus PCR) varied and these are
not necessarily interchangeable. Fourthly, the inclusion criteria
differed (various types of LRTI manifestation) between studies.
Furthermore, the outcomes measured were variable and in some
papers clinical cure was undefined.
Quality of the evidence
In addition to the above, the quality of the studies varied (Figure
1; Figure 2), with non-blinded outcomes in the majority of the
included studies.
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Potential biases in the review process
We did not identify any potential biases in the review process.
Agreements and disagreements with other
studies or reviews
Despite the commonality of M. pneumoniae LRTI in children
(attributed in up to 40% of community-acquired pneumonia as
reported by Waites 2003), there is surprisingly no RCT that has
specifically evaluated the efficacy of antibiotics for the treatment of
childhood LRTI secondary to M. pneumoniae infections acquired
in the community. Such disparity in knowledge is exemplified by
the conflicting advice given in paediatric textbooks (Phelan 1994;
Rudolph 2003). This systematic review, as well as that conducted
by Biondi 2014 showing concordant findings, reaffirms the need
for such trials to be carried out.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on a single randomised controlled trial (RCT), it is likely
that macrolides are efficacious in (at least) a small group of chil-
dren with lower respiratory tract infection (LRTI) secondary to
M. pneumoniae. However, there is insufficient evidence to draw
any specific conclusions about the efficacy of antibiotics for this
condition in children. The use of antibiotics for M. pneumoniae
LRTI has to be individualised and balanced with possible adverse
events associated with antibiotic use.
Implications for research
M. pneumoniae infection is relatively commonand its clinicalman-
ifestations range from being asymptomatic to death from its com-
plications. As respiratory symptoms are the most common symp-
toms, there is a need for high quality, double-blinded RCTs to
assess the efficacy and safety of antibiotics for LRTI secondary to
M. pneumoniae in children. Studies should consider the various
clinical and microbiological diagnostic criteria of M. pneumoniae
infection and utilise clear outcome criteria. Community studies
using polymerase chain reaction (PCR) for rapid early diagno-
sis would be useful in evaluating the efficacy of antibiotics forM.
pneumoniae for respiratory and non-respiratory manifestations, as
well as for prevention of complications and microbiological clear-
ance of M. pneumoniae.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Esposito 2005
Methods • Participants were recruited from the outpatient clinic of the Institute of Pediatrics,
University of Milan, Italy, between November 2000 and March 2002. The study group
was identified as having a history of recurrent respiratory tract infections (≥ 8 episodes/
year in < 3-year olds or ≥ 6 episodes/year in ≥ 3-year olds) and an acute lower or upper
respiratory tract infection, as diagnosed by a paediatrician and recorded on a medical
chart
• Exclusion criteria for the study group included acute streptococcal pharyngitis/
acute otitis media/CAP at enrolment, severe concomitant disease, nosocomially
acquired infection, topical/systemic steroid therapy in the 48 hours preceding study
enrolment, systemic antibiotic treatment in the 48 hours preceding study enrolment,
administration of azithromycin therapy in the week preceding study enrolment, and
intramuscular administration of benzathine penicillin G in the month preceding study
enrolment
• The control group were chosen from otherwise healthy participants undergoing
minor surgical treatment during the study period. They were to be of a similar age and
gender to the study group, without a history of respiratory tract infection or antibiotic
treatment in the 3 months before enrolment
• Acute Mycoplasma pneumoniae (M. pneumoniae) infection, Chlamydia pneumoniae
(C. pneumoniae) infection, or both was diagnosed if the child had a significant
antibody response in paired sera or if the DNA of the bacteria was detected in
nasopharyngeal aspirates, or both
Participants 560 children, aged 1 to 14 years. 352 had acute respiratory infections and a history of
recurrent respiratory tract infections (mean age = 3.6, 57.1% male, 136 with acute M.
pneumoniae infection), and 208 were in the control group (mean age = 3.9, 57.2% male,
5 with acute M. pneumoniae infection)
Interventions Patients were randomised to receive azithromycin (n = 177, 10 mg/kg/day, 3 days/week
for 3 weeks) with symptom-specific agents (acetaminophen, 10 mg/kg per dose) or
symptom-specific agents alone (n = 175)
Outcomes 1. Clinical presentations
2. Bacteriological findings
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “All the patients were randomised
in a blinded manner with a computerized
list, by the only investigator responsible for
randomisation”
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Esposito 2005 (Continued)
Comment: randomisation was appropriate
Allocation concealment (selection bias) Low risk The enrolment officer was different to
the investigator assigned to randomisation.
Consequently, the enroller was unaware
of which treatment group the participants
would be allocated to
Blinding (performance bias and detection
bias)
All outcomes
Low risk Clinical outcome assessor blinded. Al-
though patients and caregivers were not
blinded, caregivers were “instructed not to
inform the evaluator, whowas blindedwith
respect to randomisation,whether the child
had received azithromycin”
Quote: “Data entry and statistical analyses
were carried out in a blinded manner, with
SAS software”
Comment: raw data analyses were also
blinded
Follow-up?
All outcomes
Low risk Quote: “All of the enrolled patients com-
pleted the 1-month follow-up evaluation”
Quote: “A total of 339 patients (96.3%)
completed the 6-month follow-up evalua-
tion”
Comment: a high proportion of partici-
pants were followed up
Reporting of participants by allocation
group?
All outcomes
Low risk The progress of all the children in both
groupswas described, although at 6months
13 children were noted to be lost to follow-
up. The tables of results (both 1-month and
6-month follow-ups) account for all avail-
able children
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Gomez Campdera 1996
Methods • Participants were recruited from emergency department with a diagnosis of
pneumonia for the periods 1 May 1994 to 30 April 1995 and 1 December 1995 to 30
June 1996
• Inclusion and exclusion criteria were not stated
• Study participants were randomised to azithromycin or either amoxycillin-
clavulanate if under 5 years and erythromycin if over 5 years
• The method of randomisation was not described
• The study was not blinded
• There was no description of withdrawals or drop-outs
• There was no assessment of compliance
• Clinical outcomes were evaluated on day 3, 10 and 30, and chest X-ray was
repeated on day 30. Outcome measures included clinical response, hospitalisation,
radiological improvement and adverse events. Clinical response was classified as
unchanged, improved, cured or worse. These categories were not defined. Radiological
improvement at day 30 was not defined
Participants 155 children aged 6months to 16 years with pneumonia.Males = 84.Number of children
with M. pneumoniae infection in each group not stated
Interventions • Group A (n = 82): azithromycin 10 mg/kg/day OD for 3 days
• Group B (n = 73): amoxycillin-clavulanate 40 mg/kg/day, TID for 10 days if
under 5 years and erythromycin 40 mg/kg/day, TID for 10 days if over 5 years
Outcomes 1. Clinical presentations
2. Radiological findings
3. Adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Methodof randomisationwas not provided
Allocation concealment (selection bias) Unclear risk No description of allocation
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding of outcome assessor
Follow-up?
All outcomes
Unclear risk There was no description of withdrawals or
drop-outs
Reporting of participants by allocation
group?
All outcomes
Unclear risk No mention of withdrawals or drop-outs
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Harris 1998
Methods • Participants were recruited from 23 centres with a diagnosis of CAP from 31
January 1994 to 31 May 1995
• Inclusion criteria were children with clinically suspected pneumonia based on a
radiological finding and the presence of tachypnoea. In addition patients had at least 1
of the following: fever or history of fever within 24 hours, cough, white cell count >=
12,000/mm³, or chest findings suggestive of pneumonia
• Exclusion criteria were hypersensitivity to macrolides, penicillin or beta-lactam
antibiotics, pregnancy or lactation, parenteral therapy required because of severe or
multilobar pneumonia, treatment with any other systemic antibiotics within
enrolment, evidence of underlying haematological, renal, hepatic or cardiovascular
disease, chronic steroid use or concomitant treatment with theophylline,
carbamazepine, ergotamine, digitalis glycosides, terfenadine, loratadine or astemizole
• Study was a multi-centre, parallel-group in which participants were randomised 2:
1 to azithromycin or either amoxycillin-clavulanate if under 5 years and erythromycin
if over 5 years. The method of randomisation was not described
• Participants were blinded to therapy but there was no mention of blinding of
clinicians or outcome assessors
• There was a description of withdrawals or drop-outs. There was an assessment of
compliance by comparing medication bottle weights at beginning and end of study.
Participants were evaluated at 4 clinic visits: baseline; study days 2 to 5; study days 15
to 19; and 4 to 6 weeks post-therapy
• Laboratory tests were obtained at baseline and on study days 15 to 19. Chest X-
rays were obtained at baseline and 4 to 6 weeks post-therapy. Evidence of infection
with M. pneumoniae was determined by enzyme-linked immunosorbent assay and
defined as either single positive serum IgM (>= 1:10) or 4-fold increase in IgG titre
• Clinical response at study days 15 to 19 was classified as: cure, complete
resolution of signs and symptoms of pneumonia; improvement, incomplete resolution
of signs and symptoms of pneumonia; failure, persistence (or progression) of signs and
symptoms of pneumonia after 3 days of therapy or development of new clinical
findings consistent with active infection or persistence (or progression) of radiological
findings obtained when clinically indicated
• Clinical response 4 to 6 weeks post-therapy was classified as follows: cure;
complete resolution of signs and symptoms of pneumonia and improvement or
resolution of radiographic findings; failure; persistence (or progression) of signs and
symptoms of pneumonia after 3 days of therapy or development of new clinical findings
consistent with active infection or persistence (or progression) of radiological findings
• Bacteriological response was classified as follows: eradication (presumed or
proven), elimination of the original organism from the same site during or after
completion of therapy and includes cases where repeat specimens were nor obtained
and patients considered a clinical cure or improved; persistence, failure to eradicate the
organism and includes cases where specimens were not obtainable at the time
alternative therapy was instituted and the patient was considered a clinical failure.
Adverse events were monitored throughout the study by reported symptoms, physical
examinations and laboratory tests. Events were rated by severity (mild, moderate or
severe at the discretion of the investigator), organ system and relation to study drug
Participants • 456 children aged 6 months to 15 years with CAP were enrolled; males = 236
• 36 patients (25 in azithromycin group and 11 in comparator group) were
excluded for methodologic reasons, leaving 420 patients (285 in azithromycin and 135
in comparator group) available for analysis
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Harris 1998 (Continued)
• 6 children discontinued treatment because of adverse events
• The number of children with M. pneumoniae in the group randomised to
macrolide versus non-macrolide (i.e. children < 5 years) was 30, with 21 in
azithromycin group and 9 in amoxycillin-clavulanate group
Interventions • Children under 5 years only
• Group A (n = 125): azithromycin 10 mg/kg OD day 1, 1.5 mg/kg OD day 2 to 5,
and placebo day 1 to 10
• Group B (n = 63): amoxycillin-clavulanate 40 mg/kg TID day 1 to 10 and
placebo day 1 to 5
Outcomes 1. Clinical presentations
2. Radiological findings
3. Bacteriological findings
4. Adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of randomisation was not
specified
Allocation concealment (selection bias) Unclear risk Methods of allocation concealment were
not identified
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Although the study design noted it was a
“double blinded trial”, most methods of
blinding used were not specified. Partici-
pants and their caregivers were probably
blinded because “the placebo and study
drug formulations were similar in texture,
color and taste”
Follow-up?
All outcomes
Low risk Clinical and laboratory outcomes were
measured in 92.1%
Quote: “A total of 36 patients [of 456] .
.. were excluded from efficacy analysis for
methodologic reasons such as no follow-up
evaluation or concomitant antibiotic use”
Reporting of participants by allocation
group?
All outcomes
Low risk The progress of all randomised children in
each group was described, with numbers
lost to exclusion and follow-up noted
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Kogan 2003
Methods • Participants with a diagnosis of CAP were recruited from 1 January 1996 to 1
January 1999
• Inclusion criteria were children with a clinical diagnosis of radiologically
confirmed of presumed bacterial CAP, eligible for treatment with oral antibiotics and
without signs of respiratory insufficiency
• Exclusion criteria were history or evidence of chronic pathology of any organ
system, chronic pulmonary disease, history of prematurity, treatment with any
antibiotics within 5 days prior to enrolment, or known hypersensitivity to beta-lactam
antibiotics or macrolides
• The study population was divided into 2 groups according to clinical and
radiological patterns. One group included those children who presented with signs of
classic bacterial pneumonia, with high fever and chest findings of crackles or signs of
consolidation, and chest X-rays with segmental, alveolar or lobar consolidation. The
second group included patients with atypical pneumonia, with prominent and
frequently paroxysmal cough, variable fever, few clinical signs of consolidation, crackles
and wheezing, and chest X-rays with a mixed alveolar-interstitial pattern
• Participants with classic pneumonia were randomised to either amoxycillin or
azithromycin, whereas participants in the atypical pneumonia group were randomly
assigned to either azithromycin or erythromycin. The method of randomisation was
not described. There was no mention of blinding except for blinding of the radiologist
who viewed follow-up chest X-rays done on study days 7 and 14. There was a
description of withdrawals or drop-outs. There was no assessment of compliance
• Outcomes were evaluated at 3 clinic visits, on study days 3, 7 and 14. A chest X-
ray was done for each child on study days 7 and 14. Evidence of infection was
determined by indirect immunofluorescence and enzyme-linked immunosorbent assay
to test sera for IgM antibodies to M. pneumoniae. An antibody titre > 1:16 on a single
first serum specimen was considered positive for indirect immunofluorescence. Clinical
response in the classic pneumonia group was defined as the proportion of children
without fever on day 3 and/or improvement of more than 75% of radiographic
baseline findings on study day 7
Participants • 110 children aged 1 month to 14 years were enrolled
• 4 children developed serious pneumonia in the first 12 hours of enrolment and
were excluded from the study (3 from the atypical group and 1 from the classic group).
The remaining 106 completed the study
• The mean age was 4.9 years and 53 were male
• 47 met the criteria for classic pneumonia. The number of children with M.
pneumoniae in the classic group was 8, with 5 in the azithromycin group and 3 in the
amoxycillin-clavulanate group
Interventions Patients with classic pneumonia:
• Group A (n = 23): azithromycin 10 mg/kg OD for 3 days
• Group B (n = 24): amoxycillin 75 mg/kg/day in 3 divided doses for 7 days
Outcomes 1. Clinical presentations
2. Radiological findings
Notes -
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Kogan 2003 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of randomisation was not
specified
Allocation concealment (selection bias) Unclear risk Methods of allocation concealment were
not identified
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Almost no methods of blinding were spec-
ified. Participants and caregivers may have
been aware of their treatment group, as the
frequency and duration of drug adminis-
trations were different between the groups
Quote: “All chest X-rays done ... were seen
by the same radiologist, who was not famil-
iar with the patients’ clinical history and
treatment group”
Comment: radiology assessment was
blinded
Follow-up?
All outcomes
Low risk Quote: “Of the 110 enrolled patients, 4
children developed severe pneumonia in
the first 12 hr of enrolment and were ex-
cluded from the study... The remaining106
children completed the study”
Comment: no participants were lost to fol-
low-up
Reporting of participants by allocation
group?
All outcomes
Low risk The progress of all randomised children in
each group was described. Results tables
compared outcomes between groups
Ruhrmann 1982
Methods Participants were selected at the children’s hospital in Hamburg, Germany. Patients were
diagnosed with pneumonia based on chest X-ray. The study compared erythromycin
therapy with amoxycillin therapy. The duration of the study was not specified, nor were
the inclusion and exclusion criteria. Although the treatment allocation was randomised,
there was no blinding of the outcome assessor or the participant. Baseline measurements
were recorded using temperature, full blood examination, chest X-ray and cough pres-
ence. Outcome measures were noted over 10 days and were not well described, with
’clinical improvement’ being documented without any clear definition
Participants • 120 children aged 6 months to 14 years with pneumonia. Gender ratio not stated
• Number of children with M. pneumoniae infection in each group not stated
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Ruhrmann 1982 (Continued)
Interventions • Group A: erythromycin 70 to 80 mg/kg/day. Duration of therapy not stated
• Group B: amoxycillin 60 to 70 mg/kg/day. Duration of therapy not stated
Outcomes Clinical presentations
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A list of randomised numbers was used to
allocate participants into treatment groups
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding of participants or outcome as-
sessors
Follow-up?
All outcomes
Unclear risk No description of losses to follow-up was
included in the paper
Reporting of participants by allocation
group?
All outcomes
Unclear risk Unclear mention of withdrawals or drop-
outs
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Saez-Llorens 1998
Methods • Participants were recruited from emergency departments in Dallas and Panama
with a diagnosis of CAP for the period February 1996 to December 1997
• Inclusion criteria were tachypnoea, fever, cough, crackles and chest X-ray with
changes compatible with pneumonia
• Exclusion criteria were hypersensitivity to macrolides or beta-lactam antibiotics,
pregnancy, nosocomial pneumonia, use of systemic antibiotics 72 hours prior to
recruitment, chronic illness such as HIV, malignancy, cystic fibrosis, haematologic,
renal, cardiovascular, hepatic or pulmonary diseases, as well as patients on teofilin,
antihistamines, steroids or any medications with potential interaction with macrolides
• Study participants were randomised to azithromycin or either amoxycillin-
clavulanate if under 5 years and erythromycin if over 5 years. A random number list
was used and therapy assigned by pharmacy. The study was not blinded. There were 39
drop-outs, although reasons were not specified. There was no assessment of compliance
• Clinical outcomes were evaluated on days 2 to 3 and 10 to 25
• Baseline measurements were recorded using blood cultures, nasopharyngeal
aspirate cultures and PCR for M. pneumoniae and C. pneumoniae. Antibody titres
against the 2 micro-organisms were evaluated using serology. Additionally, full blood
examination, urea and electrolytes, liver function tests and tuberculin tests were used to
assess infection. Clinical response was evaluated as a cure or fail, and clinical cure was
defined as complete resolution or evident improvement of all clinical signs and
symptoms. Clinical failure was defined as persistent or progressive symptoms after 3
days of treatment
Participants • Total of 335 children aged 6 months to 15 years with CAP; 168 from Dallas with
106 under 5 years (males = 92) and 167 from Panama with 142 under 5 years (males =
98)
• 39 children dropped out. The number of children with M. pneumoniae infection
in each group was not stated
Interventions • Group A: azithromycin 10 mg/kg on day 1 and 5 mg/kg OD for days 2 to 5
• Group B: amoxycillin-clavulanate 40 mg/kg/day, TID for 10 days if under 5 years
and erythromycin 40 mg/kg/day, TID for 10 days if over 5 years
Outcomes 1. Clinical presentations
2. Bacteriological findings
3. Adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk List of randomised numbers assigned to
therapy.Unclear how randomised numbers
were generated but medication given by
pharmacy
Allocation concealment (selection bias) Low risk Medications provided by pharmacy
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Saez-Llorens 1998 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding of outcome assessor
Follow-up?
All outcomes
Unclear risk 30 drop-outs but no description of with-
drawals or drop-outs were provided in ac-
cordance to groups
Reporting of participants by allocation
group?
All outcomes
Unclear risk No mention of withdrawals or drop-outs
relative to allocated groups
Soderstrom 1991
Methods • Participants aged > 10 years were recruited with any of the following diagnoses:
sinusitis, tonsillitis, purulent nasopharyngitis or bronchitis
• Inclusion criteria defined acute bronchitis by the presence of at least 4 of the
following 5 criteria: (a) cough; (b) increased amounts of sputum; (c) rhonchus; (d)
leukocytosis (> 10 x 109 leukocytes/l); and (e) temperature > 38 degrees C
• Exclusion criteria were allergies to erythromycin or penicillin, those treated with
steroids, theophylline or antibiotics within 10 days preceding consultation
• The patients in each diagnosis group were randomly assigned to treatment with
erythromycin capsules or phenoxymethylpenicillin tablets. The patients were given
sequential patient numbers, which indicated which of the 2 treatments should be given
to each patient. The physician at the first visit and the nurse who met the patient at
follow-up visits were blinded to the intervention. There is no mention of whether the
participant was blinded to intervention. There was a description of withdrawals or
drop-outs
• Compliance was assessed by analysing urine sample collected during treatment
(days 3 to 7). The patients kept a daily record of symptoms and were reviewed by nurse
10 to 12 days after their initial visit. Evidence of M. pneumoniae infection was made on
the basis of 4-fold rise in antibody titre
• Outcome measures included clinical response and adverse reactions. Clinical
response was classified as asymptomatic, minor symptoms, streptococcal relapse/re-
infection and treatment failure. These clinical outcomes were not defined
Participants 138 patients were recruited with age range 10 to 70 years (median 32.5). Males = 56. 2
patients dropped out. Therewere only 7with bronchitis (lower respiratory tract infection)
and M. pneumoniae was identified in 1 case
Interventions • Group A: erythromycin 500 mg twice daily for 7 days
• Group B: penicillin V 800 mg twice daily for 7 days
Outcomes Clinical presentations
Notes -
Risk of bias
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Soderstrom 1991 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The paper states that patients were “ran-
domly assigned”, but simply states that “pa-
tients were given sequential patient num-
bers, which indicated which of the two
treatments should be given to each patient.
” It is unclear how treatment groups were
indicated by patient number, and so the
randomisation cannot be assessed
Allocation concealment (selection bias) Unclear risk Methods of allocation concealment were
not specified
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “The physician at the first visit and
the nurse whomet the patient at the follow-
up visit did not know which prescription
the patient had had”
Comment: the outcome assessor was
blinded. The participants and caregivers
were presumably not blinded, as they were
given prescriptions for their antibiotics
Follow-up?
All outcomes
Low risk Quote: “136/138 patients returned for fol-
low-up within 10-12 days ... The 2 re-
maining patients interrupted the treatment
within 2 days”
Comment: 98.6% of participants were
clinically assessed at the follow-up visit
Reporting of participants by allocation
group?
All outcomes
Low risk The results table clearly compared the ery-
thromycin and phenoxymethylpenicillin
groups
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Wubbel 1999
Methods • Participants were recruited from an emergency clinic at the Children’s Medical
Centre Dallas, Texas with a diagnosis of CAP from February 1996 to December 1997
• Inclusion criteria were children with tachypnoea, fever, cough or rales and an
abnormal chest X-ray consistent with pneumonia and considered to have community-
acquired infection
• Exclusion criteria were hypersensitivity to macrolides or beta-lactam antibiotics,
pregnancy or lactation, nosocomial-acquired infections, hospitalisation, systemic
antibiotic within 72 hours before enrolment, cefixime or ceftriaxone within the
previous 7 days and chronic diseases. Participants were also excluded if they were
receiving medications that had potential adverse interactions with erythromycin or
azithromycin
• Study participants were randomised to azithromycin or either amoxycillin-
clavulanate if under 5 years and erythromycin if over 5 years. A list of randomised
therapy assignments was used by research pharmacist to provide patients with either
azithromycin, amoxycillin-clavulanate or erythromycin
• There was no mention of blinding of participants, clinicians or outcome assessors,
except the radiologists who reviewed all radiographs who were not familiar with the
patient’s clinical history or results of special studies. There was a description of
withdrawals or drop-outs. There was an assessment of compliance by measuring the
volume of drug in the bottle at the 2- to 5-week visit
• Clinical evaluation occurred at enrolment, 2 to 3 days and 10 to 37 days after
start of therapy. At day 2 to 3 a telephone call was made to the caregiver to assess
symptoms, interventions and adverse reactions. Patients were assessed at weeks 2 to 5
for symptoms, adverse reactions and outcome. At this assessment bacteriological
samples were collected - nasopharyngeal and pharyngeal swabs for culture and PCR
and serum for convalescent antibody titres. A chest X-ray was repeated only if a patient
had signs of persistent or new infection. Clinical response was defined as: cure,
resolution of all signs and symptoms; improvement, incomplete resolution of all signs
and symptoms; and failure, persistence or progression after 3 days of therapy, new
clinical findings suggesting active infection or death related to pneumonia.
Bacteriological response was not defined. Adverse events were monitored throughout
the study. Evidence of infection with M. pneumoniae was determined by serology
(enzyme-linked immunosorbent assay), and culture or PCR from nasopharyngeal
swabs. Positive serology was defined as either single positive serum IgM (>= 1:10) or 4-
fold increase in IgG titre
Participants • 174 children aged 6 months to 16 years with CAP were enrolled
• 6 patients were excluded because of normal chest X-rays. 21 children were
excluded from clinical evaluation: 10 failed to return for follow-up examination and 11
did not complete treatment. Gender ratio was not mentioned. The total number of
children with M. pneumoniae was 12. However, it was not possible to determine how
many children with M. pneumoniae were in the group < 5 years who were randomised
to either azithromycin or amoxycillin-clavulanate because of the lack of individual
patient data
Interventions Children under 5 years only
Group A (n = 39): azithromycin 10 mg/kg OD day 1, followed by 5 mg/kg OD day 2
to 5
Group B (n = 49): amoxycillin-clavulanate 40 mg/kg TID day 1 to 10
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Wubbel 1999 (Continued)
Outcomes 1. Clinical presentations
2. Adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Using a randomised list of therapy
assignments...”
Comment: the method of randomisation
was not adequately specified
Allocation concealment (selection bias) Unclear risk Methods of allocation concealment were
not identified
Blinding (performance bias and detection
bias)
All outcomes
High risk Quote: “This study was a prospective, ran-
domised, unblinded trial...”
Comment: while mostly unblinded, one
outcome was partially blinded. Radio-
graphs were secondarily assessed by “radi-
ologists who were not familiar with the pa-
tients’ clinical history or results of special
studies”
Follow-up?
All outcomes
Low risk Quote: “Of the 168 patients who were as-
sessed for etiology of pneumonia, 21 were
excluded from clinical evaluation; 10 failed
to return for follow-up examination and 11
did not complete treatment”
Comment: 147/168 (87.5%) were contin-
uously followed throughout the study
Reporting of participants by allocation
group?
All outcomes
Low risk The progress of all randomised children in
each group was described
CAP: community-acquired pneumonia
IgG: immunoglobulin G
IgM: immunoglobulin M
n: number
OD: once daily
PCR: polymerase chain reaction
TID: three times a day
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Atkinson 2007 Review of studies: cited most recent evidence for treating M. pneumoniae as “inconclusive”
Block 1995 Does not fulfil the inclusion criteria. Inappropriate comparator intervention as comparison between 2 drugs
from the macrolide group - clarithromycin versus erythromycin ethylsuccinate
Bradley 2007 Does not fulfil the inclusion criteria and no specified aetiology. Inappropriate comparator intervention as
comparison between fluoroquinolone and macrolides - levofloxacin versus clarithromycin/ceftriaxone with
clarithromycin/erythromycin lactobionate. M. pneumoniae affecting the LRT and its treatments were not
specifically identified
Chien 1993 Does not fulfil the inclusion criteria. Inappropriate comparator intervention as comparison between 2 drugs
from the macrolide group - clarithromycin versus erythromycin
Esposito 2006 No focus on LRTIs. URTIs were the focus of this study
Fonseca-Aten 2006 No specified aetiology. M. pneumoniae affecting the LRT and its treatments were not specifically identified
Jensen 1967 Does not fulfil the inclusion criteria and study not randomised. Study looked at treatment of all affected
individuals with oxytetracycline and there was no placebo group. Household contacts were treated with either
oxytetracycline or placebo to determine effectiveness of oxytetracycline in secondary prevention of mycoplasma
infections. Allocation of treatment of household contacts was not randomised
Lee 2008 Does not meet the inclusion criteria and too few participants. Inappropriate comparator intervention as com-
parison between 2 drugs from macrolide groups - clarithromycin versus erythromycin. Only 26 participants
Lee 2012 Does not fulfil the inclusion criteria. A small-scale (36 participants completed), adult-focused RCT with
inappropriate comparator intervention as comparison between fluoroquinolone and combination macrolide
and cephalosporin
Manfredi 1992 Does not fulfil the inclusion criteria. Inappropriate comparator intervention as comparison between 2 drugs
from the macrolide group - azithromycin versus erythromycin
Nogeova 1997 Does not fulfil the inclusion criteria. Inappropriate comparator intervention as comparison between 2 drugs
from the cephalosporin group - ceftibuten versus cefuroxime-axetil
Ronchetti 1994 Does not fulfil the inclusion criteria. Inappropriate comparator intervention as comparison between 2 drugs
from the macrolide group - azithromycin versus josamycin
Sakata 2001 Study participants were not randomised
Schonwald 1990 Does not fulfil the inclusion criteria. Inappropriate comparator intervention as comparison between 2 drugs
from the macrolide group - azithromycin versus erythromycin
Sempertegui 2014 Does not fulfil the inclusion criteria. Inappropriate comparator intervention as comparison between standard
antimicrobial +/- zinc as an adjunct therapy
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(Continued)
Simon 2006 Article unavailable for evaluation
Vasilos 1995 Study participants were not randomised
Wu 2014 Does not fulfil the inclusion criteria. Inappropriate comparator intervention as comparison between azithro-
mycin +/- glucocorticoids as adjunct therapy
Yin 2002 Does not fulfil the inclusion criteria. Inappropriate comparator intervention as comparison between 2 drugs
from the macrolide group - oral azithromycin versus intravenous erythromycin
LRT: lower respiratory tract
LRTI: lower respiratory tract infection
RCT: randomised controlled trial
URTI: upper respiratory tract infection
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Previous searches
2012 search details
MEDLINE (Ovid)
1 Pneumonia, Mycoplasma/
2 (mycoplasma adj3 pneumonia*).tw.
3 primary atypical pneumonia.tw.
4 or/1-3
5 Mycoplasma pneumoniae/
6 (mycoplasma pneumoniae or “M. pneumoniae”).tw.
7 Mycoplasma Infections/
8 mycoplasma.tw.
9 or/5-8
10 exp Pneumonia/
11 (pneumon* or bronchopneumon* or pleuropneumon*).tw.
12 exp Bronchitis/
13 (bronchit* or tracheobronchit*).tw.
14 Respiratory Sounds/
15 wheez*.tw.
16 exp Respiratory Tract Infections/
17 (respiratory tract infection* or acute respiratory infection* or lower respiratory infection* or lower respiratory tract infection* or
lrti).tw.
18 or/10-17
19 9 and 18
20 4 or 19
21 exp Anti-Bacterial Agents/
22 exp Macrolides/
23 exp Quinolones/
24 exp Tetracyclines/
25 antibiotic*.tw,nm.
26 (macrolide* or erythromycin* or roxithromycin* or clarithromycin* or azithromycin*).tw,nm.
27 or/21-26
28 20 and 27
EMBASE
#36 #27 AND #35
#35 #30 NOT #34
#34 #31 NOT #33
#33 #31 AND #32
#32 ’human’/de AND [embase]/lim
#31 ’animal’/de OR ’nonhuman’/exp OR ’animal experiment’/de AND [embase]/lim
#30 #28 OR #29
#29 random*:ab,ti OR placebo*:ab,ti OR allocat*:ab,ti OR trial:ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR (doubl* NEXT/1
blind*):ab,ti AND [embase]/lim
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#28 ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
AND [embase]/lim
#27 #21 AND #26
#26 #22 OR #23 OR #24 OR #25
#25 erythromycin*:ab,ti OR roxithromycin*:ab,ti OR clarithromycin*:ab,ti OR azithromycin*:ab,ti OR macrolide*:ab,ti AND [em-
base]/lim
#24 antibiotic*:ab,ti AND [embase]/lim
#23 ’macrolide’/exp OR ’quinolone derivative’/exp OR ’tetracycline derivative’/exp AND [embase]/lim
#22 ’antibiotic agent’/exp AND [embase]/lim
#21 #4 OR #20
#20 #9 AND #19
#19 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18
#18 lrti:ab,ti AND [embase]/lim
#17 (infection* NEAR/1 (’respiratory tract’ OR ’acute respiratory’ OR ’lower respiratory’ OR ’lower respiratory tract’)):ab,ti AND
[embase]/lim
#16 ’respiratory tract infection’/de OR ’lower respiratory tract infection’/de AND [embase]/lim
#15 wheez*:ab,ti AND [embase]/lim
#14 ’wheezing’/de AND [embase]/lim
#13 bronchit*:ab,ti OR tracheobronchit*:ab,ti AND [embase]/lim
#12 ’bronchitis’/exp AND [embase]/lim
#11 pneumon*:ab,ti OR bronchopneumon*:ab,ti OR pleuropneumon*:ab,ti AND [embase]/lim
#10 ’pneumonia’/exp AND [embase]/lim
#9 #5 OR #6 OR #7 OR #8
#8 mycoplasma:ab,ti AND [embase]/lim
#7 ’mycoplasmosis’/de AND [embase]/lim
#6 ’mycoplasma pneumoniae’:ab,ti OR ’m. pneumoniae’:ab,ti AND [embase]/lim
#5 ’mycoplasma pneumoniae’/de AND [embase]/lim
#4 #1 OR #2 OR #3
#3 ’primary atypical pneumonia’:ab,ti AND [embase]/lim
#2 (mycoplasma NEAR/3 pneumonia):ab,ti AND [embase]/lim
#1 ’mycoplasma pneumonia’/de AND [embase]/lim
2010 search details
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 1), which contains
the Acute Respiratory Infection Group’s Specialised Register, MEDLINE (1966 to February Week 2, 2010) and EMBASE (1980 to
February 2010).
We used the following search terms for MEDLINE and CENTRAL and adapted them for EMBASE. We combined the search terms
used in MEDLINE with a sensitive search strategy for identifying child studies (Boluyt 2008) and the Cochrane Highly Sensitive
Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid
format (Lefebvre 2008).
MEDLINE (Ovid)
1 exp MYCOPLASMA/
2 exp Mycoplasma pneumoniae/
3 mycoplasma.tw.
4 “m. pneumoniae”.tw.
5 or/1-4
6 exp BRONCHITIS/
7 exp PNEUMONIA/
8 exp Respiratory Tract Infections/
9 bronchit*.tw.
10 pneumon*.tw.
11 wheez*.tw.
12 tracheobronchit*.tw.
13 respiratory tract infection*.tw.
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14 acute respiratory infection*.tw.
15 or/6-14
16 exp Anti-Bacterial Agents/
17 exp MACROLIDES/
18 exp QUINOLONES/
19 exp TETRACYCLINES/
20 antibiotic*.tw,nm.
21 (macrolide* or erythromycin or roxithromycin or clarithromycin or azithromycin).tw,nm.
22 or/16-21
23 5 and 15 and 22
24 exp Infant/
25 (infant* or infancy or newborn* or baby* or babies or neonat* or preterm* or prematur*).tw.
26 exp Child/
27 (child* or schoolchild* or school age* or preschool* or kid or kids or toddler*).tw.
28 Adolescent/
29 (adoles* or teen* or boy* or girl*).tw.
30 Minors/
31 Puberty/
32 (minor* or pubert* or pubescen*).tw.
33 exp Pediatrics/
34 (pediatric* or paediatric*).tw.
35 exp Schools/
36 (nursery school* or kindergar* or primary school* or secondary school* or elementary school* or high school* or highschool*).tw.
37 or/24-36
38 37 and 23
EMBASE
1. ’mycoplasma’/de OR ’mycoplasma pneumoniae’/de
2. ’m. pneumoniae’:ab,ti OR mycoplasma:ab,ti
3. #1 OR #2
4. ’bronchitis’/exp OR ’pneumonia’/exp
5. bronchit*:ab,ti OR pneumon*:ab,ti OR wheez*:ab,ti OR tracheobronchit*:ab,ti
6. ’respiratory tract infection’/de OR ’lower respiratory tract infection’/de
7. ’respiratory tract infection’:ab,ti OR ’respiratory tract infections’:ab,ti OR ’acute respiratory infection’:ab,ti OR ’acute respiratory
infections’:ab,ti
8. #4 OR #5 OR #6 OR #7
9. ’antibiotic agent’/exp
10. antibiotic*:ab,ti
11. ’macrolide’/exp OR ’quinolone derivative’/exp OR ’tetracycline derivative’/exp
12. macrolide*:ab,ti OR quinolone*:ab,ti OR tetracycline*:ab,ti OR erythromycin*:ab,ti OR roxithromycin*:ab,ti OR clarithromycin*:
ab,ti OR azithromycin*:ab,ti
13. #9 OR #10 OR #11 OR #12
14. #3 AND #8 AND #13
15. ’child’/exp
16. child*:ab,ti OR schoolchild*:ab,ti OR ’school age’:ab,ti OR ’school aged’:ab,ti OR ’school ages’:ab,ti OR preschool*:ab,ti OR kid:
ab,ti OR kids:ab,ti OR toddler*:ab,ti
17. ’adolescent’/exp
18. adoles*:ab,ti OR teen*:ab,ti OR boy*:ab,ti OR girl*:ab,ti
19. ’puberty’/exp
20. minor*:ab,ti OR juvenile*:ab,ti OR pubert*:ab,ti OR pubescen*:ab,ti
21. ’pediatrics’/exp
22. pediatric*:ab,ti OR paediatric*:ab,ti
23. ’school’/exp
24. (school* NEAR/2 (nursery OR primary OR secondary OR high OR elementary)):ab,ti OR kindergar*:ab,ti OR highschool*:ab,ti
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25. #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24
26. #14 AND #25
27. ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
28. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR assign*:ab,ti OR allocat*:ab,ti
OR volunteer*:ab,ti OR ((singl* OR doubl*) NEAR/2 (blind* OR mask*)):ab,ti
29. #27 OR #28
30. #26 AND #29
We imposed no language or publication restrictions.
2005 search details
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2005, Issue 1), which contains
the Acute Respiratory Infections Group’s Specialised Register; MEDLINE (1966 to February 2005) and EMBASE (1980 to December
2004).
We used the following search terms for MEDLINE and CENTRAL and adapted them for EMBASE. We combined the search terms
used in MEDLINE with the highly sensitive strategy devised by Dickersin 1994.
MEDLINE
1 exp MYCOPLASMA/
2 exp Mycoplasma pneumoniae/
3 mycoplasma
4 or/1-3
5 exp BRONCHITIS/
6 exp PNEUMONIA/
7 exp Respiratory Tract Infections/
8 bronchitis
9 pneumonia
10 atypical pneumonia
11 respiratory tract infection$
12 acute respiratory infection$
13 or/5-12
14 exp Anti-Bacterial Agents/
15 exp MACROLIDES/
16 exp QUINOLONES/
17 exp TETRACYCLINES/
18 antibiotic$
19 (macrolide$ or erythromycin or roxithromycin or clarithromycin or azithromycin)
20 or/14-19
21 exp CHILD/
22 (child or children)
23 (paediatric or pediatric)
24 or/21-23
25 4 and 13 and 20 and 24
We imposed no language or publication restrictions.
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Appendix 2. MEDLINE, CENTRAL, WHO ICTRP and ClinicalTrials.gov search strategy
MEDLINE (Ovid)
1 Pneumonia, Mycoplasma/
2 (mycoplasma adj3 pneumon*).tw.
3 primary atypical pneumonia.tw.
4 or/1-3
5 Mycoplasma pneumoniae/
6 (mycoplasma pneumoniae or “M. pneumoniae”).tw.
7 Mycoplasma Infections/
8 mycoplasma.tw.
9 or/5-8
10 exp Pneumonia/
11 (pneumon* or bronchopneumon* or pleuropneumon*).tw.
12 exp Bronchitis/
13 (bronchit* or tracheobronchit*).tw.
14 Respiratory Sounds/
15 wheez*.tw.
16 exp Respiratory Tract Infections/
17 (respiratory tract infection* or acute respiratory infection* or lower respiratory infection* or lower respiratory tract infection* or
lrti).tw.
18 or/10-17
19 9 and 18
20 4 or 19
21 exp Anti-Bacterial Agents/
22 exp Macrolides/
23 exp Quinolones/
24 exp Tetracyclines/
25 antibiotic*.tw,nm.
26 (macrolide* or erythromycin* or roxithromycin* or clarithromycin* or azithromycin*).tw,nm.
27 or/21-26
28 20 and 27
Appendix 3. EMBASE search strategy
#36 #27 AND #35
#35 #30 NOT #34
#34 #31 NOT #33
#33 #31 AND #32
#32 ’human’/de AND [embase]/lim
#31 ’animal’/de OR ’nonhuman’/exp OR ’animal experiment’/de AND [embase]/lim
#30 #28 OR #29
#29 random*:ab,ti OR placebo*:ab,ti OR allocat*:ab,ti OR trial:ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR (doubl* NEXT/1
blind*):ab,ti AND [embase]/lim
#28 ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
AND [embase]/lim
#27 #21 AND #26
#26 #22 OR #23 OR #24 OR #25
#25 erythromycin*:ab,ti OR roxithromycin*:ab,ti OR clarithromycin*:ab,ti OR azithromycin*:ab,ti OR macrolide*:ab,ti AND [em-
base]/lim
#24 antibiotic*:ab,ti AND [embase]/lim
#23 ’macrolide’/exp OR ’quinolone derivative’/exp OR ’tetracycline derivative’/exp AND [embase]/lim
#22 ’antibiotic agent’/exp AND [embase]/lim
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#21 #4 OR #20
#20 #9 AND #19
#19 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18
#18 lrti:ab,ti AND [embase]/lim
#17 (infection* NEAR/1 (’respiratory tract’ OR ’acute respiratory’ OR ’lower respiratory’ OR ’lower respiratory tract’)):ab,ti AND
[embase]/lim
#16 ’respiratory tract infection’/de OR ’lower respiratory tract infection’/de AND [embase]/lim
#15 wheez*:ab,ti AND [embase]/lim
#14 ’wheezing’/de AND [embase]/lim
#13 bronchit*:ab,ti OR tracheobronchit*:ab,ti AND [embase]/lim
#12 ’bronchitis’/exp AND [embase]/lim
#11 pneumon*:ab,ti OR bronchopneumon*:ab,ti OR pleuropneumon*:ab,ti AND [embase]/lim
#10 ’pneumonia’/exp AND [embase]/lim
#9 #5 OR #6 OR #7 OR #8
#8 mycoplasma:ab,ti AND [embase]/lim
#7 ’mycoplasmosis’/de AND [embase]/lim
#6 ’mycoplasma pneumoniae’:ab,ti OR ’m. pneumoniae’:ab,ti AND [embase]/lim
#5 ’mycoplasma pneumoniae’/de AND [embase]/lim
#4 #1 OR #2 OR #3
#3 ’primary atypical pneumonia’:ab,ti AND [embase]/lim
#2 (mycoplasma NEAR/3 pneumonia):ab,ti AND [embase]/lim
#1 ’mycoplasma pneumonia’/de AND [embase]/lim
Appendix 4. WHO ICTRP and ClinicalTrials.gov searches
1 mycoplasma AND pneumonia AND antibiotics
2 (condition - mycoplasma pneumonia) + (intervention - antibiotics) + (type - interventional study)
WH A T ’ S N E W
Last assessed as up-to-date: 8 July 2014.
Date Event Description
8 July 2014 New search has been performed A new author joined the review team.
8 July 2014 New citation required but conclusions have not changed Searches updated. We did not include any new trials and
we excluded three new trials (Lee 2012; Sempertegui 2014;
Wu 2014).
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H I S T O R Y
Protocol first published: Issue 3, 2004
Review first published: Issue 3, 2005
Date Event Description
15 March 2012 New citation required but conclusions have not
changed
A new author joined the review team.
13 March 2012 New search has been performed Searches conducted.
22 February 2010 New search has been performed Searches conducted. One new included trial (Esposito
2005) and six new excluded trials (Atkinson 2007;
Bradley 2007; Esposito 2006; Fonseca-Aten 2006; Lee
2008; Simon 2006) have been added to the update.
22 February 2010 New citation required and conclusions have changed A new author joined the review team. The conclusion
has changed to reflect the new included trial
22 July 2008 Amended Converted to new review format.
23 May 2005 Amended Review first published Issue 3, 2005
C O N T R I B U T I O N S O F A U T H O R S
In the first version, John Gavranich (JG) wrote the protocol, independently selected papers for inclusion, assessed quality, extracted
data and wrote the review. Anne Chang (AC) edited and co-wrote the protocol, independently selected papers for inclusion, assessed
quality, extracted data, and edited and co-wrote the review.
For the 2010 updated version, Selamawit Mulholland (SM) and AC selected papers for inclusion. SM included the ’Risk of bias’
tables and figures and updated the included/excluded studies and their characteristics and the text accordingly. These were adapted and
checked by AC. The revised version was reviewed by all review authors.
For the 2012 update, Malcolm Gillies (MG) and AC reviewed the literature searches.
In this 2014 review update Samantha Gardiner (SG) and AC independently assessed the literature searches. SG updated the text body
and table of excluded studies, which was checked by AC and the revised version reviewed by all authors.
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D E C L A R A T I O N S O F I N T E R E S T
Samantha J Gardiner: none known.
John B Gavranich: none known.
Anne B Chang is a recipient of a GlaxoSmithKline grant towards the study of microbia in bronchoalveolar lavage (BAL), a topic
unrelated to this review. AC has received funding from Johnson and Johnson (J&J) to present at the World Paediatric series, though
the talk does not endorse nor make reference to J&J. AC is also the principal investigator on a study examining azithromycin for
bronchiolitis in Indigenous children.
S O U R C E S O F S U P P O R T
Internal sources
• West Moreton Health Service District, Ipswich, Australia.
• Royal Children’s Hospital, Brisbane, Australia.
External sources
• NHMRC, Australia.
Practitioner Fellowship salary support for AC (grant 545216)
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Mycoplasma pneumoniae; Amoxicillin-Potassium Clavulanate Combination [therapeutic use]; Anti-Bacterial Agents [∗therapeutic
use]; Azithromycin [therapeutic use]; Bronchitis [∗drug therapy; microbiology]; Community-Acquired Infections [drug therapy; mi-
crobiology]; Erythromycin [therapeutic use]; Pneumonia, Mycoplasma [∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Child; Humans
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